Cryptococcal antigen screening and preemptive therapy in patients initiating antiretroviral therapy in resource-limited settings: a proposed algorithm for clinical implementation.
about
Multisite validation of cryptococcal antigen lateral flow assay and quantification by laser thermal contrastLATERAL FLOW ASSAY FOR CRYPTOCOCCAL ANTIGEN: AN IMPORTANT ADVANCE TO IMPROVE THE CONTINUUM OF HIV CARE AND REDUCE CRYPTOCOCCAL MENINGITIS-RELATED MORTALITYIntegrated therapy for HIV and cryptococcosisNeurological immune reconstitution inflammatory response: riding the tide of immune recoveryCryptococcal meningitis: epidemiology and therapeutic options.Mortality in patients with HIV-1 infection starting antiretroviral therapy in South Africa, Europe, or North America: a collaborative analysis of prospective studiesLong term 5-year survival of persons with cryptococcal meningitis or asymptomatic subclinical antigenemia in Uganda.The prevalence of cryptococcal antigenemia in newly diagnosed HIV patients in a Southwest London cohort.Cryptococcal Antigen Screening in Patients Initiating ART in South Africa: A Prospective Cohort StudySerotype sensitivity of a lateral flow immunoassay for cryptococcal antigenEvolution of Cryptococcal Antigen Testing: What is new?New Insights into HIV/AIDS-Associated Cryptococcosis.Comparison of cryptococcal antigenemia between antiretroviral naïve and antiretroviral experienced HIV positive patients at two hospitals in Ethiopia.Asymptomatic cryptococcemia in resource-limited settings.Think fungus–prevention and control of fungal infections.Asymptomatic cryptococcal antigenemia is associated with mortality among HIV-positive patients in Indonesia.Meningitis in HIV-positive patients in sub-Saharan Africa: a review.The cryptococcal antigen lateral flow assay: A point-of-care diagnostic at an opportune time.Recent advances in AIDS-related cryptococcal meningitis treatment with an emphasis on resource limited settings.Evaluation of screening and treatment of cryptococcal antigenaemia among HIV-infected persons in Soweto, South Africa.The current treatment landscape: other fungal diseases (cryptococcosis, fusariosis and mucormycosis).Cryptococcal antigen prevalence in HIV-infected Tanzanians: a cross-sectional study and evaluation of a point-of-care lateral flow assay.Integrating clinical services for HIV, tuberculosis, and cryptococcal disease in the developing world: a step forward with 2 novel diagnostic testsHIV-Associated Cryptococcal Disease in Resource-Limited Settings: A Case for "Prevention Is Better Than Cure"?Evaluation of a point-of-care immunoassay test kit 'StrongStep' for cryptococcal antigen detection.Cryptococcal Antigen Screening in Asymptomatic HIV-Infected Antiretroviral Naïve Patients in Cameroon and Evaluation of the New Semi-Quantitative Biosynex CryptoPS Test.An audit of the screen-and-treat intervention to reduce cryptococcal meningitis in HIV-positive patients with low CD4 count
P2860
Q24620256-D6485555-B5C4-44A5-B404-BA8770DC7954Q26783210-80FF96FA-FD50-4DBF-B1E7-387E3B3C9F34Q28077707-11874183-77E8-4671-8608-FD41247F624BQ28082309-428D3138-CFE1-45D3-B4E0-027F9977D8E7Q33633343-0B27E04D-CBE1-4934-AD62-62E5B4106719Q34155253-62759380-5E83-456D-94DF-1426DFCBBABFQ34516367-55FCDD78-8D74-43E1-BEE5-F57409F826F9Q36518475-BD9BFEBC-AD6F-4189-A496-0D8F0FA71D83Q36543833-7B084B2A-13BE-4E76-9EE3-7E3D3697BD45Q36757799-0A2F6E35-14CF-4D50-AA50-F2D0D4021259Q36873953-0379528C-9C22-40DD-AC5A-DF0D0B963EB2Q37156556-474984CC-6E72-4420-A37F-F99C8118E125Q37215923-AA039341-4E01-415C-82B4-74263A24A394Q37259640-FBADEB36-B6E8-4AB1-A268-6B59BA9637FBQ37262023-4DC54846-6F04-496E-A669-36820DB15014Q37530766-2B2A12FB-D618-4754-994B-369E8AD02605Q38259519-4B5599D9-BD94-409B-A6F3-D6864B5FF001Q38328870-F58B5C04-0A10-4E66-898E-452FC21BC4F8Q38851467-F9254E48-38AA-4DEE-867C-043AB85CF45BQ39030373-D9468630-7BB5-4337-98D2-F9EE2009D7BEQ39189670-68097C0F-D093-4600-BCE2-D69E53BE7E90Q39413554-79AADB9E-0F15-49E5-88D4-A051A1718DF8Q41585583-26260F99-C19E-40BB-A492-283541D810A1Q47646979-5759D5E5-B9FD-44F8-892D-8B13811CFAC9Q48303014-1DDC4F77-A0EA-4819-AA5B-5F39159B2CE7Q52624536-620B4C15-3612-4437-A02C-9E884C6D7172Q58794920-D56B5FE6-A545-4DA3-AA53-EC0551829735
P2860
Cryptococcal antigen screening and preemptive therapy in patients initiating antiretroviral therapy in resource-limited settings: a proposed algorithm for clinical implementation.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Cryptococcal antigen screening ...... m for clinical implementation.
@en
type
label
Cryptococcal antigen screening ...... m for clinical implementation.
@en
prefLabel
Cryptococcal antigen screening ...... m for clinical implementation.
@en
P2093
P2860
P50
P356
P1476
Cryptococcal antigen screening ...... m for clinical implementation.
@en
P2093
Benjamin J Park
Nelesh Govender
Nicky Longley
Tom Chiller
P2860
P304
P356
10.1177/1545109712459077
P577
2012-09-26T00:00:00Z